Novel approaches to the management of myeloma

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Standard therapy for multiple myeloma, which accounts for 10% of all hematologic malignancies, has been autologous stem cell transplantation (ASCT), alkylator-based chemotherapy, and corticosteroids. Several advances have been made in the treatment of multiple myeloma over the past decade, especially the arrival of new, active agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid). These have shown significant clinical activity as single agents. Trials are ongoing to incorporate these new agents into the various stages of treatment and to combine them with other effective treatment modalities, including ASCT.

Original languageEnglish (US)
Pages (from-to)621-625
Number of pages5
Issue number5
StatePublished - 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel approaches to the management of myeloma'. Together they form a unique fingerprint.

Cite this